Related Experiment Video

Updated: Sep 20, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of

R Knecht1, S Peters, O Adunka

  • 1Department of Otorhinolaryngology, University of Frankfurt, Medical School, 60590 Frankfurt/M., Germany.

Anticancer Research
|August 5, 2003
PubMed
Abstract

Insights

Combining cisplatin with anti-epidermal growth factor receptor (EGFR) therapy shows enhanced tumor growth inhibition. This combined approach demonstrates efficacy regardless of EGFR expression levels, suggesting broader applicability in cancer treatment.

Area of Science:

  • Oncology
  • Cancer Research
  • Pharmacology

Background:

  • Previous studies indicated antitumor efficacy of monoclonal antibodies against EGFR is EGFR-content dependent.
  • The current study investigates if the cumulative effect of cisplatin and anti-EGFR therapy is also dependent on EGFR expression.

Purpose of the Study:

  • To determine if the combined therapeutic effect of cisplatin and anti-EGFR antibodies is influenced by EGFR expression levels in tumors.
  • To evaluate the efficacy of combination therapy compared to monotherapy.

Main Methods:

  • Utilized xenotransplanted carcinomas with varying EGFR expression levels.
  • Administered monoclonal antibodies against EGFR (EMD 72000, EMD 55900), cisplatin, and a combination of both treatments.

Main Results:

  • Monoclonal antibodies alone achieved EGFR-dependent tumor growth reduction.
  • Cisplatin monotherapy showed differential effects based on EGFR content (inhibitory on low EGFR, no effect on high EGFR).
  • Combination therapy resulted in significant tumor growth inhibition independent of EGFR expression, surpassing monotherapy effects.

Conclusions:

  • The combination of anti-EGFR antibodies and cisplatin offers a potent therapeutic strategy.
  • This combination therapy's EGFR-independent efficacy suggests potential for broader clinical application in upcoming trials.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...